Union Springs, BIOSAFE enter agreement to commercialize HM4100 products

NewsGuard 100/100 Score

Kentucky-based Union Springs Pharmaceuticals announced today an agreement with BIOSAFE® of Pittsburgh to market products containing the patented and novel antimicrobial polymer, HM4100. Similar to its flagship product, MyClyns® (antimicrobial germ spray), Union Springs Pharmaceuticals will identify the products as MyClyns Antimicrobial Surface Treatments and will be the first company to bring these unique products to the market.

“The launch of the MyClyns products containing the patented HM4100 represents a big step forward in antimicrobial protection, offering significant benefits in performance and versatility. We believe that Union Springs is strategically well-positioned to build a market presence around our unique technology.”

HM4100 is a residual long-term antimicrobial that has demonstrated effectiveness against the proliferation of bacteria (including MRSA, VREF, and Staph), mold, mildew, and even certain viruses such as Influenza A (H5N1-bird flu and H1N1-swine flu are Influenza A viruses). This environmentally friendly, odorless solution can be used not only on hard surfaces such as: tables; desks; counters and equipment, but also on porous surfaces such as: bedding; clothing; carpeting and furniture. Furthermore, the solution provides freshness to surfaces by combating deterioration and discoloration while it reduces odors.

BIOSAFE HM4100 is a unique solution that provides long-lasting antimicrobial protection. Its unique mode of action inhibits growth of microorganisms through a physical process, not a harsh chemical interaction, thus limiting a microbe's ability to adapt and become resistant over time. HM4100 is non-leaching and non-toxic, and has a unique safety profile that is uncommon to most antimicrobials that leach potentially harmful chemicals such as polychlorinated biphenyl and heavy metals.

Union Springs Pharmaceuticals plans to immediately market five new products containing the revolutionary HM4100 antimicrobial treatment. It will be introduced in various sprays, surface wipes, fabric refreshers and as a laundry additive. Additional products treated with HM4100 will be marketed in the near future.

"The new MyClyns line of products will offer efficacious treatment that works over time but is environmentally friendly. It is of particular value to families and organizations where a long-lasting antimicrobial will substantially reduce the amount of time, energy and cleaning materials they currently must use in their current cleaning cycles," Union Springs Pharmaceuticals Chairman Roger Griggs said. "Additionally, the MyClyns antimicrobial products take a unique approach. Unlike conventional cleaning products, MyClyns Surface Protectant is highly versatile because it cannot only protect surfaces vulnerable to pathogen growth but it can safely be impregnated into many of them as well. We studied every product in this category, and hands down the HM4100 is the most effective and safest product in the category."

BIOSAFE's CEO Max Fedor commented, "The launch of the MyClyns products containing the patented HM4100 represents a big step forward in antimicrobial protection, offering significant benefits in performance and versatility. We believe that Union Springs is strategically well-positioned to build a market presence around our unique technology."

Source: Union Springs Pharmaceuticals

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study offers promising targets for universal influenza B vaccine